Top

Published in:

01-03-2015 | Original Article

Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

Authors: Hirotsugu Kenmotsu, Tateaki Naito, Keita Mori, Ryo Ko, Akira Ono, Kazushige Wakuda, Hisao Imai, Tetsuhiko Taira, Haruyasu Murakami, Masahiro Endo, Toshiaki Takahashi

Published in: Cancer Chemotherapy and Pharmacology | Issue 3/2015

Abstract

Purpose

The prognosis of non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) is unclear. To assess the prognosis of NSCLC patients with ILD treated with platinum-based chemotherapy, we retrospectively analyzed the clinical course of those with ILD.

Methods

One hundred and four NSCLC patients with ILD treated with platinum-based chemotherapy at Shizuoka Cancer Center between August 2002 and June 2013 were retrospectively reviewed.

Results

The combination of carboplatin with paclitaxel was most frequently used as the first-line treatment for NSCLC patients with ILD (61 %). The overall response rate was 38 % in 104 NSCLC patients with ILD treated with platinum-based chemotherapy. In all patients, median progression-free survival and overall survival were 4.8 and 9.9 months, respectively. During first-line platinum-based chemotherapy, 9 % of the 104 patients with ILD developed chemotherapy-related exacerbation of ILD. Multivariate analysis demonstrated that clinical stage was a significantly independent prognostic factor (hazard ratio 0.517; 95 % confidence interval 0.314–0.842, p = 0.0079). Patients with clinical stage IV or recurrence after surgical resection showed poor prognosis (median survival time 8.5 months).

Conclusions

Our study suggests that the prognosis of NSCLC patients with ILD is poor. The risk of exacerbation of ILD in patients treated with platinum-based chemotherapy as the first-line treatment was slightly lower than in previous reports.

Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388CrossRefPubMed

Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128CrossRefPubMed

Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefPubMed

Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-Positive lung cancer. N Engl J Med 368:2385–2394CrossRefPubMed

Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91:S18–S23CrossRefPubMedCentralPubMed

Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348–1357CrossRefPubMed

Azzoli CG, Temin S, Aliff T et al (2011) 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831CrossRefPubMedCentralPubMed

Besse B, Adjei A, Baas P et al (2014) 2nd ESMO consensus conference on lung cancer: non-small-cell lung cancer first-line/second and further lines in advanced disease. Ann Oncol 25:1475–1484CrossRefPubMed

Pavlakis N, Bell DR, Millward MJ et al (1997) Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 80:286–291CrossRefPubMed

10.

Read WL, Mortimer JE, Picus J (2002) Severe interstitial pneumonitis associated with docetaxel administration. Cancer 94:847–853CrossRefPubMed

11.

Yoh K, Kenmotsu H, Yamaguchi Y et al (2010) Severe interstitial lung disease associated with amrubicin treatment. J Thorac Oncol 5:1435–1438CrossRefPubMed

12.

Kenmotsu H, Naito T, Kimura M et al (2011) The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6:1242–1246CrossRefPubMed

13.

Collard HR, Moore BB, Flaherty KR et al (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 176:636–643CrossRefPubMedCentralPubMed

14.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRefPubMed

15.

Shukuya T, Ishiwata T, Hara M et al (2010) Carboplatin plus weekly paclitaxel treatment in non-small cell lung cancer patients with interstitial lung disease. Anticancer Res 30:4357–4361PubMed

16.

Kinoshita T, Azuma K, Sasada T et al (2012) Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia. Oncol Lett 4:477–482PubMedCentralPubMed

17.

Okuda K, Hirose T, Oki Y et al (2012) Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease. Anticancer Res 32:5475–5480PubMed

18.

Watanabe N, Taniguchi H, Kondoh Y et al (2013) Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration 85:326–331CrossRefPubMed

19.

Minegishi Y, Takenaka K, Mizutani H et al (2009) Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 48:665–672CrossRefPubMed

20.

Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323CrossRefPubMed

21.

Okamoto I, Yoshioka H, Morita S et al (2010) Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. J Clin Oncol 28:5240–5246CrossRefPubMed

22.

Ohe Y, Yamamoto S, Suzuki K et al (2001) Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer 37:54–63CrossRefPubMed

23.

Sanuki N, Ono A, Komatsu E et al (2012) Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res 53:110–116CrossRefPubMed

24.

Minegishi Y, Sudoh J, Kuribayasi H et al (2011) The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71:70–74CrossRefPubMed

25.

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98CrossRefPubMed

26.

Tamiya A, Naito T, Miura S et al (2012) Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 32:1103–1106PubMed

27.

Kuribayashi K, Voss S, Nishiuma S et al (2012) Safety and effectiveness of pemetrexed in patients with malignant pleural mesothelioma based on all-case drug-registry study. Lung Cancer 75:353–359CrossRefPubMed

28.

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304CrossRef

Title: Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
Authors: Hirotsugu Kenmotsu
Tateaki Naito
Keita Mori
Ryo Ko
Akira Ono
Kazushige Wakuda
Hisao Imai
Tetsuhiko Taira
Haruyasu Murakami
Masahiro Endo
Toshiaki Takahashi
Publication date: 01-03-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 3/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2670-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2015

Myelotoxicity of carboplatin is increased in vivo in db/db mice, the animal model of obesity-associated diabetes mellitus

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study

Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma

Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing

Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer

Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo

Keynote webinar | Spotlight on antibody–drug conjugates in cancer